13 Biotech Stocks with Huge Upside Potential

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Analysts’ Upside Potential as of June 9: 65.04%

JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800.

Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares is “very much overdone.”

JPMorgan pointed out that IL-33 was never a key component of its model, though. The company stressed that, even without accounting for any pipeline contribution, Dupixent, Eylea, and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’ solid cash position alone warrants a valuation far higher than current levels. JPMorgan anticipates several catalysts over the next six months that will help reset its value.

Recently, the firm’s valuation was under pressure due to its IL-33 program’s lackluster Phase results. JPMorgan is still optimistic in spite of this, concentrating on important assets like Dupixent and Eylea that support the company’s financial stability. The company’s updated $800 estimate, which reflects confidence in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s core business and future potential milestones, still suggests significant upside.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, develops, and commercializes drugs to treat eye disease, cardiovascular disease, cancer, and inflammation. It is one of the stocks with the huge upside potential.